MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical End...
April 25 2019 - 9:45AM
MannKind Corporation (Nasdaq:MNKD) today announced
additional data supporting the distinct clinical profile of Afrezza
will be presented in an e-poster presentation on Thursday, April
25, 2019 at the 28th Annual Scientific and Clinical Congress of the
American Association of Clinical Endocrinologists (AACE 2019).
“These data demonstrate that Afrezza’s
ultra-rapid onset uniquely affects early post-prandial glucose
levels and other measures of mealtime glycemic control,” stated Dr.
David Kendall, Chief Medical Officer of MannKind.
Poster Presentation Highlights
Title: Ultra-rapid Profile of
Technosphere® Insulin Inhalation Powder Mimics Time-Action Profile
of Physiologic Absorption of Glucose From Mixed-Meal Tolerance
Tests in Type 2 Diabetes AACE 2019 Thursday, April 25th
(1:30-2:00pm Poster Presentation Area, Monitor 14)
Presenter: David Kendall, MD, Chief
Medical Officer, MannKind Corporation
Highlights:
- Compared to insulin lispro, the ultra-rapid absorption of
Afrezza provides significantly better control of early
post-prandial glucose levels due to an earlier increase in glucose
disposal and a faster suppression of endogenous glucose production.
The duration of this effect is dose dependent.
- Compared to insulin lispro, Afrezza was associated with lower
postprandial glucagon and C-peptide levels and produced a faster
decrease in free fatty acid levels.
- The ultra-rapid profile of Afrezza closely approximates the
time-action profile of physiologic insulin needs after a meal in
patients with Type 2 Diabetes.
About AACE Annual Meeting
The AACE 2019 conference is an opportunity for
healthcare professionals specializing in endocrinology, diabetes,
and metabolism to gather to discuss the latest scientific
advancements and best practices for enhancing patient care, and
enjoy educational sessions led by the world's most respected
endocrine clinicians.
About Afrezza®
Available by prescription, Afrezza® (insulin
human) Inhalation Powder is a rapid-acting inhaled insulin
indicated to improve glycemic control in adult patients with
diabetes mellitus. Afrezza consists of a dry powder
formulation of human insulin delivered from a small and portable
inhaler. Administered at the beginning of a meal, Afrezza dissolves
rapidly upon inhalation to the lung and passes quickly into the
bloodstream (in less than one minute). This rapid absorption allows
Afrezza to begin reducing blood sugar levels within about 12
minutes of administration. Afrezza is available in 4-unit,
8-unit and 12-unit single-dose cartridges of insulin powder that
can be used, as prescribed by a health care professional, in
combination with other diabetes medications to achieve target blood
sugar levels. For Afrezza doses exceeding 12 units, patients
may use a combination of existing cartridge strengths. For more
information on Afrezza, please visit www.afrezza.com.
About MannKind
MannKind Corporation (NASDAQ:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
MannKind Contact:Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024